Value of PET/CT versus PET and CT performed as separate investigations in patients with Hodgkin's disease and non-Hodgkin's lymphoma

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 33, Issue 12, 2006, Pages 1417-1425

  La Fougère, Christian ^a   Hundt, Walter ^a   Bröckel, Nicole ^a   Pfluger, Thomas ^a   Haug, Alexander ^a   Scher, Bernhard ^a   Hacker, Marcus ^a   Hahn, Klaus ^a   Reiser, Maximilan ^a   Tiling, Reinhold ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

18F FDG; Computed tomography; Hodgkin's disease; Non Hodgkin's lymphoma; PET CT; Positron emission tomography

Indexed keywords

FLUORODEOXYGLUCOSE F 18; FUROSEMIDE; IOPROMIDE; SCOPOLAMINE BUTYL BROMIDE;

ADULT; AGED; ARTICLE; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; FEMALE; FOLLOW UP; HODGKIN DISEASE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; POSITRON EMISSION TOMOGRAPHY;

ADULT; AGED; FEMALE; HODGKIN DISEASE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 33845364589     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-006-0171-x     Document Type: Article

References (43)

1. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International prognostic factors project on advanced Hodgkin's disease. N Engl J Med 1998;339(21):1506-1514
2. Hicks RJ, Mac Manus MP, Seymour JF. Initial staging of lymphoma with positron emission tomography and computed tomography. Semin Nucl Med 2005;35(3):165-175
3. Guppy AE, Tebbutt NC, Norman A, Cunningham D. The role of surveillance CT scans in patients with diffuse large B-cell non-Hodgkin's lymphoma. Leuk Lymphoma 2003;44(1):123-125
4. Canellos GP. Residual mass in lymphoma may not be residual disease. J Clin Oncol 1988;6(6):931-933
5. Schiepers C, Filmont JE, Czernin J. PET for staging of Hodgkin's disease and non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 2003;30 Suppl 1:S82-S88
6. Gambhir SS, Czernin J, Schwimmer J, Silverman DH, Coleman RE, Phelps ME. A tabulated summary of the FDG PET literature. J Nucl Med 2001;42(5 Suppl):1S-93S
7. Sasaki M, Kuwabara Y, Koga H, Nakagawa M, Chen T, Kaneko K, et al. Clinical impact of whole body FDG-PET on the staging and therapeutic decision making for malignant lymphoma. Ann Nucl Med 2002;16(5):337-345
8. Stumpe KD, Urbinelli M, Steinert HC, Glanzmann C, Buck A, von Schulthess GK. Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: effectiveness and comparison with computed tomography. Eur J Nucl Med 1998;25(7):721-728
9. Steinert HC. [PET/CT in lymphoma patients.]. Radiologe 2004;44(11):1060-1067
10. 18F]FDG for therapy response monitoring in lymphoma patients. Eur J Nucl Med Mol Imaging 2003;30 Suppl 1:S97-S105
11. 18F-fluorodeoxyglucose for initial staging of patients with Hodgkin's disease. Ann Hematol 2002;81(1):20-25
12. 18F-fluorodeoxyglucose positron emission tomography in lymphoma. Leuk Lymphoma 2003;44(1):15-22
13. Wirth A, Seymour JF, Hicks RJ, Ware R, Fisher R, Prince M, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma. Am J Med 2002;112(4):262-268
14. Kumar R, Maillard I, Schuster SJ, Alavi A. Utility of fluorodeoxyglucose-PET imaging in the management of patients with Hodgkin's and non-Hodgkin's lymphomas. Radiol Clin North Am 2004;42(6):1083-1100
15. Glazer GM, Gross BH, Quint LE, Francis IR, Bookstein FL, Orringer MB. Normal mediastinal lymph nodes: number and size according to American Thoracic Society mapping. AJR Am J Roentgenol 1985;144(2):261-265
16. Lister TA, Crowther D, Sutcliffe SB, Glatstein E, Canellos GP, Young RC, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989;7(11):1630-1636
17. Freudenberg LS, Antoch G, Schutt P, Beyer T, Jentzen W, Muller SP, et al. FDG-PET/CT in re-staging of patients with lymphoma. Eur J Nucl Med Mol Imaging 2004;31(3):325-329
18. Schaefer NG, Hany TF, Taverna C, Seifert B, Stumpe KD, von Schulthess GK, et al. Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PETand CTat staging and restaging - do we need contrast-enhanced CT? Radiology 2004;232(3):823-829
19. Goerres GW, von Schulthess GK, Steinert HC. Why most PET of lung and head-and-neck cancer will be PET/CT. J Nucl Med 2004;45 Suppl 1:66S-71S
20. Goerres GW, Stupp R, Barghouth G, Hany TF, Pestalozzi B, Dizendorf E, et al. The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate. Eur J Nucl Med Mol Imaging 2005;32(2):153-162
21. Goerres GW, Kamel E, Seifert B, Burger C, Buck A, Hany TF, et al. Accuracy of image coregistration of pulmonary lesions in patients with non-small cell lung cancer using an integrated PET/CT system. J Nucl Med 2002;43(11):1469-1475
22. Hany TF, Steinert HC, Goerres GW, Buck A, von Schulthess GK. PET diagnostic accuracy: improvement with in-line PETCT system: initial results. Radiology 2002;225(2):575-581
23. Sakai F, Sone S, Kiyono K, Maruyama A, Oguchi M, Kawai T, et al. Computed tomography of neck lymph nodes involved with malignant lymphoma: comparison with ultrasound. Radiat Med 1991;9(6):203-208
24. Eisenberg PJ, Papanicolaou N, Lee MJ, Yoder IC. Diagnostic imaging in the evaluation of renal lymphoma. Leuk Lymphoma 1994;16(1-2):37-50
25. Bechtold RE, Karstaedt N, Wolfman NT, Glass TA. Prolonged hepatic enhancement on computed tomography in a case of hepatic lymphoma. J Comput Assist Tomogr 1985;9(1):186-189
26. Pombo F, Rodriguez E, Caruncho MV, Villalva C, Crespo C. CT attenuation values and enhancing characteristics of thoracoabdominal lymphomatous adenopathies. J Comput Assist Tomogr 1994;18(1):59-62
27. Feuerbach S, Lukas P, Gmeinwieser J. [False interpretations of computed tomograms in malignant lymph node diseases of the pelvis and abdomen]. Digitale Bilddiagn 1984;4(4):176-180
28. Flecknoe-Brown S. Positron emission tomography scanning in patients with lymphoma. Intern Med J 2005;35(2):137-138
29. Hutchings M, Eigtved AI, Specht L. FDG-PET in the clinical management of Hodgkin lymphoma. Crit Rev Oncol Hematol 2004;52(1):19-32
30. Reske SN. PET and restaging of malignant lymphoma including residual masses and relapse. Eur J Nucl Med Mol Imaging 2003;30 Suppl 1:S89-S96
31. 18FDG-PET with CT scans in the evaluation of patients with residual and recurrent Hodgkin's lymphoma. Oncol Rep 2001;8(6):1393-1399
32. Hermann S, Wormanns D, Pixberg M, Hunold A, Heindel W, Jurgens H, et al. Staging in childhood lymphoma: differences between FDG-PET and CT. Nuklearmedizin 2005;44(1):1-7
33. Kazama T, Faria SC, Varavithya V, Phongkitkarun S, Ito H, Macapinlac HA. FDG PET in the evaluation of treatment for lymphoma: clinical usefulness and pitfalls. Radiographics 2005;25(1):191-207
34. Moog F, Bangerter M, Diederichs CG, Guhlmann A, Merkle E, Frickhofen N, et al. Extranodal malignant lymphoma: detection with FDG PET versus CT. Radiology 1998;206(2):475-481
35. Carr R, Barrington SF, Madan B, O'Doherty MJ, Saunders CA, van der Walt J, et al. Detection of lymphoma in bone marrow by whole-body positron emission tomography. Blood 1998;91(9):3340-3346
36. Moog F, Kotzerke J, Reske SN. FDG PET can replace bone scintigraphy in primary staging of malignant lymphoma. J Nucl Med 1999;40(9):1407-1413
37. Moog F, Bangerter M, Kotzerke J, Guhlmann A, Frickhofen N, Reske SN. 18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow. J Clin Oncol 1998;16(2):603-609
38. 18F-FDG PET in malignant lymphoma: significance of positive findings. Eur J Nucl Med Mol Imaging 2005;32(7):749-756
39. Allen-Auerbach M, Yeom K, Park J, Phelps M, Czernin J. Standard PET/CT of the chest during shallow breathing is inadequate for comprehensive staging of lung cancer. J Nucl Med 2006;47(2):298-301
40. Goerres GW, Kamel E, Heidelberg TN, Schwitter MR, Burger C, von Schulthess GK. PET-CT image co-registration in the thorax: influence of respiration. Eur J Nucl Med Mol Imaging 2002;29(3):351-360
41. Bockisch A, Beyer T, Antoch G, Freudenberg LS, Kuhl H, Debatin JF, et al. Positron emission tomography/computed tomography - imaging protocols, artifacts, and pitfalls. Mol Imaging Biol 2004;6(4):188-199
42. Tatsumi M, Cohade C, Nakamoto Y, Fishman EK, Wahl RL. Direct comparison of FDG PET and CT findings in patients with lymphoma: initial experience. Radiology 2005;237(3):1038-1045
43. Bar-Shalom R, Yefremov N, Guralnik L, Gaitini D, Frenkel A, Kuten A, et al. Clinical performance of PET/CT in evaluation of cancer: additional value for diagnostic imaging and patient management. J Nucl Med 2003;44(8):1200-1209